BioVendor Acquired by Archimed SAS in Major Diagnostics Deal

Archimed SAS has acquired BioVendor Group, marking the seventh investment by its MED III fund. This particular fund, which amassed a total of €650 million by its close in 2021, has now invested approximately half of its resources into small-cap healthcare enterprises valued between €50 million and €150 million. The acquisition is focused on companies like BioVendor that have not been previously owned by private equity firms, aligning perfectly with Archimed’s strategy of acquiring and growing healthcare companies via primary buyouts. Archimed is distinguished as the sixth-best performing buyout firm globally, largely due to its remarkable cash-to-cash returns and consistent distribution of liquidity to investors. This deal further exemplifies their successful investment strategy in the healthcare sector, amidst a competitive landscape where liquidity was challenging for many.